Morgan Stanley’s Gyre Therapeutics GYRE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $60.2K | Sell |
8,641
-45,857
| -84% | -$356K | ﹤0.01% | 6350 |
|
|
2025
Q4 | $385K | Buy |
54,498
+45,517
| +507% | +$351K | ﹤0.01% | 5647 |
|
|
2025
Q3 | $67K | Sell |
8,981
-26,277
| -75% | -$200K | ﹤0.01% | 6304 |
|
|
2025
Q2 | $259K | Buy |
35,258
+21,228
| +151% | +$185K | ﹤0.01% | 5746 |
|
|
2025
Q1 | $108K | Sell |
14,030
-1,211
| -8% | -$13.3K | ﹤0.01% | 5971 |
|
|
2024
Q4 | $184K | Sell |
15,241
-2,981
| -16% | -$38.2K | ﹤0.01% | 5819 |
|
|
2024
Q3 | $229K | Buy |
18,222
+10,949
| +151% | +$141K | ﹤0.01% | 5705 |
|
|
2024
Q2 | $86.8K | Buy |
7,273
+1,567
| +27% | +$21.5K | ﹤0.01% | 6010 |
|
|
2024
Q1 | $99.7K | Buy |
+5,706
| New | +$103K | ﹤0.01% | 5989 |
|
|
2023
Q4 | – | Sell |
-6,516
| Closed | -$47.1K | – | 7858 |
|
|
2023
Q3 | $47.1K | Buy |
6,516
+1,443
| +28% | +$9.66K | ﹤0.01% | 6192 |
|
|
2023
Q2 | $26.8K | Buy |
5,073
+2,513
| +98% | +$9.01K | ﹤0.01% | 6462 |
|
|
2023
Q1 | $7.95K | Sell |
2,560
-2,241
| -47% | -$8.52K | ﹤0.01% | 6948 |
|
|
2022
Q4 | $19K | Sell |
4,801
-13
| -0.3% | -$53 | ﹤0.01% | 6711 |
|
|
2022
Q3 | $18K | Sell |
4,814
-60
| -1% | -$762 | ﹤0.01% | 6833 |
|
|
2022
Q2 | $65K | Sell |
4,874
-3,489
| -42% | -$23.2K | ﹤0.01% | 6492 |
|
|
2022
Q1 | $41K | Sell |
8,363
-60,201
| -88% | -$298K | ﹤0.01% | 6793 |
|
|
2021
Q4 | $470K | Buy |
68,564
+58,153
| +559% | +$994K | ﹤0.01% | 5592 |
|
|
2021
Q3 | $321K | Sell |
10,411
-3,737
| -26% | -$123K | ﹤0.01% | 5745 |
|
|
2021
Q2 | $458K | Buy |
14,148
+6,177
| +77% | +$212K | ﹤0.01% | 5579 |
|
|
2021
Q1 | $302K | Buy |
7,971
+5,506
| +223% | +$252K | ﹤0.01% | 5420 |
|
|
2020
Q4 | $116K | Buy |
2,465
+1,959
| +387% | +$84.8K | ﹤0.01% | 5850 |
|
|
2020
Q3 | $16K | Sell |
506
-1,818
| -78% | -$71.2K | ﹤0.01% | 6137 |
|
|
2020
Q2 | $103K | Buy |
2,324
+739
| +47% | +$34.7K | ﹤0.01% | 5383 |
|
|
2020
Q1 | $52K | Sell |
1,585
-33
| -2% | -$1.52K | ﹤0.01% | 5452 |
|
|
2019
Q4 | $83K | Sell |
1,618
-5,397
| -77% | -$226K | ﹤0.01% | 5705 |
|
|
2019
Q3 | $258K | Sell |
7,015
-25,253
| -78% | -$1.36M | ﹤0.01% | 5002 |
|
|
2019
Q2 | $1.78M | Buy |
32,268
+31,380
| +3,534% | +$1.96M | ﹤0.01% | 3866 |
|
|
2019
Q1 | $54K | Sell |
888
-2,178
| -71% | -$140K | ﹤0.01% | 5631 |
|
|
2018
Q4 | $181K | Sell |
3,066
-320
| -9% | -$23.6K | ﹤0.01% | 5320 |
|
|
2018
Q3 | $273K | Sell |
3,386
-1,316
| -28% | -$104K | ﹤0.01% | 5312 |
|
|
2018
Q2 | $412K | Buy |
4,702
+611
| +15% | +$107K | ﹤0.01% | 5224 |
|
|
2018
Q1 | $792K | Buy |
4,091
+3,657
| +843% | +$682K | ﹤0.01% | 4712 |
|
|
2017
Q4 | $44K | Buy |
434
+401
| +1,215% | +$20.5K | ﹤0.01% | 5862 |
|
|
2017
Q3 | $1K | Buy |
+33
| New | +$989 | ﹤0.01% | 6445 |
|
|
2016
Q4 | – | Sell |
-1
| Closed | – | – | 6536 |
|
|
2016
Q3 | $0 | Sell |
1
-120
| -99% | -$18.1K | ﹤0.01% | 6525 |
|
|
2016
Q2 | $21K | Buy |
121
+31
| +34% | +$5.29K | ﹤0.01% | 5831 |
|
|
2016
Q1 | $17K | Buy |
90
+3
| +3% | +$723 | ﹤0.01% | 5969 |
|
|
2015
Q4 | $31K | Sell |
87
-74
| -46% | -$29.1K | ﹤0.01% | 5891 |
|
|
2015
Q3 | $84K | Sell |
161
-47
| -23% | -$71.7K | ﹤0.01% | 5495 |
|
|
2015
Q2 | $457K | Sell |
208
-24
| -10% | -$48.1K | ﹤0.01% | 4780 |
|
|
2015
Q1 | $542K | Buy |
232
+12
| +5% | +$24.8K | ﹤0.01% | 4604 |
|
|
2014
Q4 | $455K | Sell |
220
-29
| -12% | -$55.9K | ﹤0.01% | 4723 |
|
|
2014
Q3 | $496K | Buy |
249
+13
| +6% | +$32.1K | ﹤0.01% | 4581 |
|
|
2014
Q2 | $840K | Buy |
236
+90
| +62% | +$294K | ﹤0.01% | 4199 |
|
|
2014
Q1 | $546K | Buy |
146
+57
| +64% | +$211K | ﹤0.01% | 4488 |
|
|
2013
Q4 | $293K | Buy |
89
+31
| +53% | +$122K | ﹤0.01% | 4821 |
|
|
2013
Q3 | $242K | Sell |
58
-90
| -61% | -$362K | ﹤0.01% | 4765 |
|
|
2013
Q2 | $498K | Buy |
+148
| New | +$563K | ﹤0.01% | 4260 |
|
Other funds holding GYRE
VCM
SS
VFT
VPM
Morgan Stanley's GYRE Position: Q1 2026 in Review
Morgan Stanley reduced its Gyre Therapeutics (GYRE) stake by 84% in Q1 2026, selling an estimated $356K and leaving 8,641 shares worth $60.2K. The position accounts for ﹤0.01% of the portfolio, ranked #6350.
Morgan Stanley first reported a position in GYRE in Q2 2013 and has held it in 48 quarters since. The position peaked at $1.78M in Q2 2019. 56 funds tracked by Wall St. Rank hold GYRE as of Q1 2026.
- Morgan Stanley held 8,641 shares of Gyre Therapeutics worth $60.2K as of Q1 2026.
- Morgan Stanley sold 45,857 Gyre Therapeutics shares in Q1 2026, an estimated $356K.
- Gyre Therapeutics made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #6350 holding.
- Morgan Stanley first reported a position in Gyre Therapeutics in Q2 2013 and has held it in 48 quarters since.
- Morgan Stanley's Gyre Therapeutics position peaked at $1.78M in Q2 2019.
- 56 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q1 2026.
Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.